Since late 2024, we have been aligned with ABL, Inc. Together we offer scalable support for specialty advanced therapeutic developers from research to commercialization with United States and European locations.
Ascend can support your journey at any scale for:
Gene therapies
Immunotherapies
Oncolytics
Vaccines
Development Based Expertise
All our work comes from a background of developing therapies. When we struggled to find our own CDMOs, we became one. Discover the difference of working with a team with deep chemistry, manufacturing & controls (CMC).
Decades of Biologics, Innovation & Expertise
60+ years custom biologics & vaccines support with 20+ AAV development expertise
Next gen technologies & analytics complemented by deep regulatory acumen
Onsite fill-finish capabilities in multiple US locations
Latest News & Insights
24 November 2025
Advancing rAAV Characterization with Oxford Nanopore Sequencing
In this recorded webinar hosted by Oxford Nanopore Technologies, scientists from Ascend Advanced Therapies discuss how they have implemented Oxford Nanopore...
Read More10 November 2025
Ascend Unveils Proprietary Enhancers That Significantly Improve AAV Yields Without Compromising Quality
New data from Ascend’s R&D team demonstrate up to 3-fold increase in AAV yields supporting greater efficiency and scalability...
Read More5 November 2025
Ascend Advanced Therapies Identifies microRNAs That Enhance AAV Vector Production
Screen of more than 2,400 microRNAs identifies multiple candidates that significantly enhance vector productivity without compromising quality attributes. Munich,...
Read More8 October 2025
European Patent on Ascend Advanced Therapies’ EpyQ® AAV Plasmid Technology Successfully Defended at the EPO
Rockville, Maryland – 8th October, 2025 – Ascend Advanced Therapies (Ascend), a gene-to-GMP development partner, today announced that its...
Read MoreTake your career to a new level with Ascend
Email us at hello@www.ascend-adv.com to share your enthusiasm and expertise and one of our team will be in touch.